Role of drug therapy for sustained ventricular tachyarrhythmias.
L Brent Mitchell
Index: Cardiol. Clin. 26(3) , 405-18, vi, (2008)
Full Text: HTML
Abstract
Antiarrhythmic drug therapy, broadly defined, is the mainstay of treatment and prevention of ventricular tachycardia (VT)/ventricular fibrillation (VF), which can lead to sudden death. This article evaluates the evidence for and appropriate use of class I antiarrhythmic drugs, class III antiarrhythmic drugs, beta-blockers, nondihydropyridine calcium-channel blockers, statins, angiotensin enzyme inhibitors, angiotensin receptor blockers, aldosterone blockers, and digoxin for antiarrhythmic benefits in patients who have a propensity for VT/VF and therefore are at risk of sudden death.
Related Compounds
Related Articles:
Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
2000-11-01
[Expert Opin. Investig. Drugs 9(11) , 2705-15, (2000)]
2006-07-01
[Europace 8(7) , 549-57, (2006)]
2008-02-01
[J. Cardiovasc. Electrophysiol. 19(2) , 172-7, (2008)]
2007-11-01
[J. Pharmacol. Sci. 105(3) , 229-39, (2007)]
Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes.
2010-01-01
[J. Pharmacol. Sci. 114(1) , 111-4, (2010)]